entertainment -WSS

entertainment

author：leisure time 2025-09-27 09:45:17 - browse：738

FDA's Peter Marks talks with STAT's Adam Feuerstein — Peter Marks, the FDA's top regulator of gene therapies (right), speaks with STAT's Adam Feuerstein in San Francisco. Sarah Gonzalez/Peopletography for STAT

SAN FRANCISCO — Peter Marks, the Food and Drug Administration’s top regulator of gene therapies, seems very comfortable with granting some form of full approval to Elevidys, the Sarepta Therapeutics gene therapy for Duchenne muscular dystrophy, based on his comments to me on Monday night during our “fireside chat” at a STAT event.

To be clear, Marks declined to comment specifically about the ongoing FDA review of Elevidys. I tried. However, Marks described a “hypothetical case” in the context of my Sarepta questions that clearly suggested the failure of an Elevidys confirmatory study in October didn’t bother him all that much.

“Hypothetically, if you had a product that used an aggregate scale and all of the components of that aggregate scale looked pretty good, or nearly all of them look pretty good, but the aggregate, for various reasons, didn’t come out perfectly. We approved products based on that,” Marks told me.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： CDC says it’s too soon to assess risk posed by Covid subvariant

WSS

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

Abortion policy in the spotlight at Republican debate

California store owner shot dead in dispute over displaying Pride flag: Police

FDA seeking to stop procedures at two unregulated stem cell clinics

How the drug

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

focus

entertainment

Wikipedia

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

House passes resolution saying Israel isn't a 'racist or apartheid state'

United colonoscopy coverage change 'may cost lives,' doctors say

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Medicare details structure of new drug price negotiation program

Study: Hearing aids may slow cognitive decline in those at risk

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

A Theranos scientist

Novavax promises a turnaround & Lilly roils the obesity market

Why you get paid to donate plasma but not blood

focus

What we know about the American soldier detained in North Korea

Meadows told special counsel he could not recall Trump ever declassifying Mar

US soldier in North Korean custody after crossing DMZ line

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

Study: Hearing aids may slow cognitive decline in those at risk

Biden administration sends mixed signals on US soldier who crossed into North Korea

explore

leisure time

focus

leisure time